AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06225310
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucocorticoid, steroid
Trial: NCT04850495
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04850495
Drug: Vincristine Sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04850495
Drug: Zanubrutinib
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT06680609
Drug: Nefopam 20 MG/ML
RxNorm normalized name: nefopam 20 MG/ML
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The unlabeled interventional drug solution was administered one at the beginning of surgery. A 10 mL solution containing nefopam 20 mg was infused over 20 min
Trial: NCT05814666
Drug: Danvatirsen
RxNorm normalized name: Danvatirsen
DrugBank: Danvatirsen (DB14825)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danvatirsen is a STAT3 targeting drug.
Trial: NCT05814666
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2
Trial: NCT06680739
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab 1500 mg IV every 4 weeks
Trial: NCT06680739
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab 300 mg IV as a single dose
Trial: NCT06058702
Drug: Delta-9-THC
RxNorm normalized name: delta-9-THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active Delta-9-THC (0.036 mg/kg) administered intravenously over 20 minutes.
Trial: NCT06116526
Drug: Dupilumab - Discontinuation
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug injections are discontinued.
Trial: NCT06116526
Drug: Dupilumab - Dose Reduction
RxNorm normalized name: reductic acid
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The drug is given as a subcutaneous injection.
Trial: NCT06116526
Drug: Dupilumab - Standard Dose
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The drug is given as a subcutaneous injection.
Trial: NCT05526430
Drug: Harmine Hydrochloride Capsules
RxNorm normalized name: carminate
DrugBank: Harmine (DB07919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules taken orally
Trial: NCT06370000
Drug: Oral Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral Azacitidine, 300mg PO Daily during days 1-14 of a 28 day cycle for up to 6 cycles.
Trial: NCT05936528
Drug: Lactoferrin
RxNorm normalized name: Lactoferrin
DrugBank: Lactoferrin (DB16555)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antioxidant, immunomodulatory, anti-inflammatory, antimicrobial, and antiviral effect
Trial: NCT05409911
Drug: S-217622
RxNorm normalized name: TPG-S
DrugBank: Tocofersolan (DB11635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet for oral administration
Trial: NCT06321302
Drug: BI 764524
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 764524
Trial: NCT06321302
Drug: Sham comparator to BI 764524
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham comparator to BI 764524
Trial: NCT06321302
Drug: Aflibercept (Eylea®) - US only
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aflibercept (Eylea®) - US only
Trial: NCT05025332
Drug: NNZ-2591
RxNorm normalized name: NNZ-2591
DrugBank: NNZ-2591 (DB15601)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
Trial: NCT05602194
Drug: Calaspargase Pegol
RxNorm normalized name: Calaspargase pegol
DrugBank: Calaspargase pegol (DB14730)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given standard of care calaspargase pegol
Trial: NCT05602194
Drug: Pegaspargase
RxNorm normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given standard of care pegaspargase
Trial: NCT05253651
Drug: tucatinib
RxNorm normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300mg given by mouth (orally) twice daily
Trial: NCT05253651
Drug: trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8mg/kg loading dose will be given into the vein (IV; intravenously) on Cycle 1 day 1, followed by 6mg/kg given by IV every 3 weeks thereafter.
Trial: NCT05253651
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5mg/kg given by IV every 2 weeks
Trial: NCT05253651
Drug: cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400mg/m2 loading dose will be given by IV on Cycle 1 day 1, followed by 250mg/m2 given by IV weekly
Trial: NCT05253651
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 85mg/m2 given by IV every 2 weeks. Component of mFOLFOX6.
Trial: NCT05253651
Drug: levoleucovorin
RxNorm normalized name: Levoleucovorin
DrugBank: Levoleucovorin (DB11596)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg/ m2 given by IV every 2 weeks. May be given in place of leucovorin. Component of mFOLFOX6.
Trial: NCT05239624
Drug: Enfortumab vedotin
RxNorm normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enfortumab vedotin will be administered at 1.25 mg/kg on day 1 and day 8 of each 21-day cycle, for up to 6 cycles.
Trial: NCT05239624
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab will be administered on day 1 of each cycle, every 21 days, for 6 cycles.
Trial: NCT01852682
Drug: PA21
RxNorm normalized name: Sucroferric oxyhydroxide
DrugBank: Iron sucrose (DB09146)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04721457
Drug: Distilled Water
RxNorm normalized name: Distilled Water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group
Trial: NCT04721457
Drug: 1% Povidone Iodine (PVP-I)
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Over-the-counter antiseptic mouth rinse
Trial: NCT04721457
Drug: 1.5% Hydrogen Peroxide (H2O2)
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Over-the-counter antiseptic mouth rinse
Trial: NCT04721457
Drug: 0.075% Cetylpyridinium Chloride (CPC)
DrugBank: Cetylpyridinium (DB11073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Over-the-counter antiseptic mouth rinse
Trial: NCT04721457
Drug: 0.1% Sodium Hypochlorite
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Over-the-counter antiseptic mouth rinse
Trial: NCT06233903
Drug: 18F-mFBG
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F-mFBG positron emission tomography with CT (PET/CT) or positron emission tomography with MRI (PET/MRI)
Trial: NCT05648500
Drug: Cenerimod
RxNorm normalized name: Cenerimod
DrugBank: Cenerimod (DB12705)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg.
Trial: NCT06530732
Drug: Lecanemab
RxNorm normalized name: Lecanemab
DrugBank: Lecanemab (DB14580)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The newly approved anti-beta-amyloid (Aβ) monoclonal antibody Lecanemab can delay AD progression but is only suitable for patients in the early stages. For those with moderate to severe AD, Lecanemab is not effective.
Trial: NCT05200403
Drug: Crisaborole 2%
RxNorm normalized name: CRISABOROLE 2% OINT,TOP
DrugBank: Crisaborole (DB05219)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The adult caregiver will apply a thin layer of Crisaborole 2% topically on their child participant twice a day for 2 weeks.
Trial: NCT06422273
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endobronchial (topical) tranexamic acid used prophylactically prior to performing transbronchial biopsies in lung transplant recipients
Trial: NCT06706271
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 IU of Vitamin D
Trial: NCT05986240
Drug: Danvatirsen
RxNorm normalized name: Danvatirsen
DrugBank: Danvatirsen (DB14825)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danvatirsen (AZD9150) is a selective, high-affinity, antisense oligonucleotide inhibitor of signal transducer and activator of transcription 3 (or STAT3).
Trial: NCT06708481
Drug: resin infilteration
RxNorm normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improvement of white spot lesions appearance by infiltration occurs due to a change in the refractive index since the refractive index of enamel (1.62-1.65) is different than that of air (1.00). Infiltration of the lesions with an infiltrate that has a refractive index of 1.52 is able to mask the lesion
Trial: NCT06710782
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients underwent intra-articular hyaluronic acid injection.
Trial: NCT06707246
Drug: Secukinumab 300 MG; Tofacitinib 11mg
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tofacitinib tablet 11mg per tablet; Secukinumab 150mg/ml
Trial: NCT06777537
Drug: Talniflumate
RxNorm normalized name: talniflumate
DrugBank: Talniflumate (DB09295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talniflumate was administered
Trial: NCT04669821
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loading Dose：0.5 mg/kg，Maintenance Dose：Maintenance is started at1.5 mg/kg/h, and the dose can be adjusted up and down by 0.25-0.5mg/kg/h.
Trial: NCT04576806
Drug: Fluid bolus
RxNorm normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of fluid bolus of crystalloid of 500ml over 15 minutes
Trial: NCT04708145
Drug: Aflibercept Injection
RxNorm normalized name: aflibercept Injection
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal 2mg aflibercept injection
Trial: NCT06710821
Drug: Liposomal irinotecan in combination with vincristine and temozolomide
RxNorm normalized name: vincristine liposome
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine: 1.5 mg/m², iv, d1. l Temozolomide 150 mg/m²/d, iv drip, d1-5. l Irinotecan liposomal RP dose, iv infusion over 90 min, d1. Q3W, 4 cycles expected until disease progression or intolerable toxicity occurs
Trial: NCT06194929
Drug: Defactinib
RxNorm normalized name: Defactinib
DrugBank: Defactinib (DB12282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defactinib will be administered at 200 mg twice daily orally per arm description.
Trial: NCT06194929
Drug: Avutometinib
RxNorm normalized name: Avutometinib
DrugBank: Avutometinib (DB15254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avutometinib will be administered at 3.2 mg twice a week orally per arm description.
Trial: NCT06194929
Drug: Encorafenib
RxNorm normalized name: encorafenib
DrugBank: Encorafenib (DB11718)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Encorafinib administered orally per arm description.
Trial: NCT05113641
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study nephrologist will prescribe the oral alkali therapy (sodium bicarbonate) and the medications will be dispensed by the Seven Oaks Hospital pharmacy.
Trial: NCT06708455
Drug: Chemotherapy Prior to RAPA-201 Therapy
RxNorm normalized name: BRASSICA RAPA POLLEN
DrugBank: RAPA-201 (DB18446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin + Paclitaxel Regimen (CP Regimen)
Trial: NCT06536309
Drug: Sacubitril-valsartan
RxNorm normalized name: Sacubitril-Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sacubitril-valsartan titrated to maximally targeted dose
Trial: NCT06536309
Drug: Valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan titrated to maximally targeted dose
Trial: NCT05073458
Drug: parsaclisinib
RxNorm normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: parsaclisib will be administered QD orally
Trial: NCT05480878
Drug: Nitazoxanide 500Mg Oral Tablet
RxNorm normalized name: Nitazoxanide 500mg Oral tablet
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects will receive Nitazoxanide 500gm twice daily for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
Trial: NCT05480878
Drug: Escitalopram 10mg
RxNorm normalized name: Escitalopram 10mg Oral tablet
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects will receive Escitalopram 10 mg/day for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
Trial: NCT06339593
Drug: Hyperpolarized Xe129
RxNorm normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperpolarized Xe MRI is FDA Approved for Adults and Children 12 and above We have been performing Xe MRI for research in human subjects for over 20 years, and for over 10 years at CCHMC. Recent FDA approval of hyperpolarized Xe MRI for ventilation stands as a testament to its safety and value as a modern tool for exploring lung disease and function. Earlier studies using Xe MRI have shown its efficacy in exploring CF and other lung diseases in pediatric and adult populations, and it has been found to be much more sensitive to early lung disease than traditional metrics like spirometry and MBW
Trial: NCT05920343
Drug: Rivaroxaban 10 MG
RxNorm normalized name: rivaroxaban 10 MG
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The intervention in the experimental arm will be rivaroxaban, 10 mg PO once daily (prophylactic dosing) for 180 days after the start of systemic therapy or until one of the primary study outcomes occurs (VTE or major bleeding).
Trial: NCT06408714
Drug: Nalmefene Injection
RxNorm normalized name: nalmefene Injection
DrugBank: Nalmefene (DB06230)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects in this arm will be administered intravenous nalmefene with a dosing scheme of:~0.5 mg Nalmefene IV~If an adequate response (increase in RR of at least 5 breaths per minute and minimum respiratory rate of 12 breaths per minute or reduction in ETCO2 to 40 mm Hg) is not attained after 2 minutes, an additional 1.0 mg nalmefene will be administered.~If an adequate response is not attained after an additional 2 minutes of observation, naloxone may be administered as a rescue agent at the treating physician's discretion.
Trial: NCT06408714
Drug: Naloxone Injection
RxNorm normalized name: naloxone Injection
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects in this arm will be administered intravenous naloxone with a dosing scheme of:~0.4 mg Naloxone IV~If an adequate response (increase in RR of at least 5 breaths per minute and minimum respiratory rate of 12 breaths per minute or reduction in ETCO2 to 40 mm Hg) is not attained after 2 minutes, an additional 0.4 mg of naloxone will be administered.~If an adequate response is not attained after an additional 2 minutes of observation, naloxone may be administered as a rescue agent at the treating physician's discretion.
Trial: NCT04704843
Drug: Guselkumab
RxNorm normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Guselkumab will be administered as IV infusion (induction dose) and SC injection.
Trial: NCT05912517
Drug: Nipocalimab
RxNorm normalized name: Nipocalimab
DrugBank: Nipocalimab (DB16257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nipocalimab will be administered as an intravenous infusion.
Trial: NCT06061471
Drug: AK111
RxNorm normalized name: Alpelisib
DrugBank: Alpelisib (DB12015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AK111 regimen 1-subcutaneous injection,until week 24.
Trial: NCT06061471
Drug: AK111
RxNorm normalized name: Alpelisib
DrugBank: Alpelisib (DB12015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AK111 regimen 2-subcutaneous injection,until week 24.
Trial: NCT04951128
Drug: Tranexamic acid injection
RxNorm normalized name: tranexamic acid Injection
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (100 mg/mL concentration; 0.5 mL) will be added to local anesthetic mixture of 2% lidocaine with epinephrine (2.25 mL) and 0.5% bupivacaine with epinephrine (2.25mL).
Trial: NCT06303583
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: paclitaxel, 50 mg/m2, QW\*5
Trial: NCT06303583
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: area under the curve of2mg/mL/min, QW\*5
Trial: NCT06303583
Drug: tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg Q3W, 2cycles
Trial: NCT05334654
Drug: Enoxaparin Sodium
RxNorm normalized name: Enoxaparin Sodium
DrugBank: Enoxaparin (DB01225)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enoxaparin will be subcutaneously administered at a dosage from 4000 to 8000 twice daily according
Trial: NCT05334654
Drug: Bivalirudin
RxNorm normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bivalirudin will be intravenously administered to obtain an activated prothrombin time (aPTT) of 1.5 fold of the normal values.
Trial: NCT05094908
Drug: Arnica Tincture
RxNorm normalized name: Arnica Tincture
DrugBank: Arnica montana (DB14297)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arnika tincture is a topical plant-based preparation legally authorized in Colombia and in the countries of the European community, the product of this study is Arnika tinktur Gehrlicher (5249), manufactured by Gehrlicher Pharmazeutische Extrakte GmbH, Germany. According to the European Pharmacopoeia, the solution is a 70% hydroethanolic tincture prepared from the flowers of A. montana L, and composed at least 0.04% of sesquiterpene lactones. Arnica tincture will be applied topically by each participant on all lesions until day 30 or 45, depending on the regimen to be evaluated.
Trial: NCT06315231
Drug: Edaravone dexborneol sublingual tablet
DrugBank: Borneol (DB11288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive one edaravone dexborneol sublingual tablet twice daily for 24 weeks
Trial: NCT05343572
Drug: Plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A 20mg single dose of PLERIXAFOR is administered subcutaneously the evening prior to scheduled standard of care surgery for women with AS, AE or RIF for peripheral mobilization of stem cells. For subjects weighing \>83 kilogram, the dosing is a single dose of 0.24 milligram per kilogram.
Trial: NCT04251182
Drug: 15mg T3D-959
RxNorm normalized name: Reovirus type 3 (strain dearing) (t3d) (mammalian orthoreovirus 3)
DrugBank: Pelareorep (DB17284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration once daily in the morning
Trial: NCT05615818
Drug: Futibatinib
RxNorm normalized name: Futibatinib
DrugBank: Futibatinib (DB15149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 20 mg once a day (QD)
Trial: NCT05615818
Drug: Ivosidenib
RxNorm normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose 500 mg QD
Trial: NCT05615818
Drug: Zanidatamab
RxNorm normalized name: Zanidatamab
DrugBank: Zanidatamab (DB15471)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: Patients \< 70 kg: 1800 mg every 3 weeks (Q3W), Patients ≥ 70 kg: 2400 mg Q3W
Trial: NCT05615818
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Loading dose 8 mg/kg, then 6 mg/kg Q3W (Combination with neratinib)
Trial: NCT05615818
Drug: Neratinib
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose: 240 mg QD (combination with trastuzumab)
Trial: NCT05615818
Drug: Encorafenib
RxNorm normalized name: encorafenib
DrugBank: Encorafenib (DB11718)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose: 450 mg QD (Combination with binimetinib)
Trial: NCT05615818
Drug: Binimetinib
RxNorm normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose: 45 mg twice a day (BID) (Combination with encorafenib)
Trial: NCT05615818
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose: 200 mg QD or 300 mg QD
Trial: NCT05615818
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose: 25 mg/m2 IV on days 1 and 8 Q3W (CISGEM)